AzTrials
AzTrials

Prostate CancerPhase 2NCT07247175

The Impact of Force Feedback in the dV5 Robotic Surgical System on Learning Curve and Safety in Robot-Assisted Radical Prostatectomy - A Prospective, Single-Center, Investigator-Initiated Clinical Trial

A Phase 2 study testing Force-feedback on and Forece-feedback off in people with Prostate Cancer, run by Seong Soo Jeon at 1 site in South Korea.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This single-center, investigator-initiated prospective clinical study aims to evaluate the impact of the Force Feedback function of the da Vinci 5 (dV5) robotic surgical system on surgical skill acquisition and intraoperative safety during robot-assisted radical prostatectomy (RARP). Read more about this study

Who is it for?
Ages 19 years and older, men only
Conditions the study is for
Prostate Cancer
What is being tested?
Force-feedback on and Forece-feedback off
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteSouth Korea
Study dates
1 Jan 2026to 31 Dec 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male patients aged ≥19 years.
  • Histologically confirmed localized prostate cancer, clinical stage T1-T3a, N0, M0.
  • Scheduled to undergo robot-assisted radical prostatectomy (RARP) at Samsung Medical Center.
  • No radiologic evidence of distant metastasis, and disease deemed surgically resectable via robotic approach.
  • Medically fit for general anesthesia and laparoscopic surgery, classified as ASA physical status I-III.
  • Baseline erectile function preserved, defined as IIEF-5 ≥12 within 6 months prior to surgery.
  • Provided written informed consent for participation after full explanation of the study.

Who cannot join

  • Locally advanced or metastatic prostate cancer (clinical stage ≥T3b, N1, or M1**).
  • Prostate volume ≥60 cc on preoperative MRI, which may complicate robotic dissection standardization.
  • History of pelvic radiotherapy for any malignancy.
  • Previous androgen deprivation therapy (ADT) or other hormonal therapy for prostate cancer.
  • History of prior prostate surgery, such as TURP or HoLEP.
  • History of spinal cord injury or major pelvic surgery that may alter pelvic anatomy.
Show all 10Show fewer
  • Medical contraindications to robotic/laparoscopic surgery or general anesthesia (e.g., severe cardiopulmonary disease, ASA ≥ IV).
  • Anatomic limitations (e.g., extreme obesity or deformity) precluding safe robotic access.
  • Device or software malfunction preventing proper activation or deactivation of the Force Feedback system.
  • Any other condition deemed inappropriate for study participation by the principal investigator (e.g., cognitive impairment affecting consent or follow-up).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jiwoong Yu Clinical professor contact

821068887981

jiwoong082.yu@samsung.com

South Korea1 site, 1 recruiting
  • Samsung Medical Center

    Soeul

    Jiwoong Yu Clinical professor, 821068887981, jiwoong082.yu@samsung.com

    Recruiting

Other trials in South Korea

About this study

This single-center, investigator-initiated prospective clinical study aims to evaluate the impact of the Force Feedback function of the da Vinci 5 (dV5) robotic surgical system on surgical skill acquisition and intraoperative safety during robot-assisted radical prostatectomy (RARP). Although robotic surgery is well established in urology, the absence of tactile sensation remains a major limitation of previous systems. The new dV5 platform incorporates real-time haptic (force) feedback, potentially reducing excessive tissue traction and improving surgical precision.

A total of 60 patients with clinically localized prostate cancer will be enrolled at Samsung Medical Center. Two surgeons (one faculty and one trainee) will each perform 30 RARP cases, with Force Feedback ON/OFF randomly assigned for each case. The primary endpoints are (1) mean traction force and (2) total instrument path length during seminal vesicle dissection. Secondary endpoints include surgical performance metrics (time, clutch counts), intraoperative safety, postoperative complications, and patient-reported outcomes (IPSS, IIEF-5, EPIC-CP, ICIQ-UI SF). Data will be analyzed using mixed-effects models accounting for surgeon-level random effects.

This study seeks to provide quantitative evidence on how Force Feedback enhances surgical learning efficiency, precision, and patient safety in next-generation robotic prostate surgery.

Read the detailed description

This prospective, single-institution, investigator-initiated clinical trial investigates how the Force Feedback (haptic sensing) technology in the da Vinci 5 (dV5) robotic surgery platform influences technical skill acquisition and safety in robot-assisted radical prostatectomy (RARP). The study is conducted at Samsung Medical Center (Seoul, Korea) under the supervision of Professor Seong Soo Jeon and Dr. Jiwoong Yu from the Department of Urology.

Robotic-assisted surgery has revolutionized minimally invasive prostate cancer treatment, but conventional robotic systems (e.g., da Vinci Xi) lack tactile feedback, forcing surgeons to rely solely on visual cues. This limitation may lead to excessive force application and increase the risk of tissue injury. The dV5 system introduces a Force Feedback mechanism that allows surgeons to feel real-time resistance transmitted through the robotic arms. Preclinical reports suggest this reduces applied forces by up to 40-50% and improves precision, especially during the learning phase. However, objective clinical data quantifying these benefits are limited.

The present trial will enroll 60 patients diagnosed with clinically localized prostate cancer (cT1-T3a, N0, M0) eligible for RARP. Two surgeons-a senior faculty (expert) and a urology resident (trainee)-will each perform 30 RARP cases. For each surgery, the Force Feedback function will be randomly assigned (ON vs. OFF) while maintaining identical operative conditions. The seminal vesicle dissection step is chosen as the standardized assessment phase since it is technically demanding yet safe for educational evaluation.

Primary endpoints are:

Mean traction force applied to tissue (N)

Total instrument path length (m) during seminal vesicle dissection

Secondary endpoints include:

Surgical performance metrics: operative time, clutch counts, peak force, efficiency indicators, and cumulative sum (CUSUM) learning curves.

Safety parameters: estimated blood loss, complications (graded by Clavien-Dindo), hospital stay, and biochemical recurrence.

Patient-reported outcomes: urinary, sexual, and overall quality of life assessed by validated questionnaires (IPSS, IIEF-5, EPIC-CP, ICIQ-UI SF).

Procedural efficiency metrics such as lens-cleaning frequency and suction count.

All operations will be video-recorded and digitally logged using dV5 Case Insight software, which captures objective performance indicators (OPIs) including instrument trajectory, applied force, and clutch frequency. Statistical analysis will use linear mixed-effects models with Force Feedback status and case sequence as fixed effects, and surgeon ID as a random effect, allowing adjustment for intra-surgeon correlations and learning effects.

Safety monitoring follows institutional IRB and KGCP guidelines. All adverse events (AEs) and device deficiencies will be documented, with serious adverse events (SAEs) reported within 24 hours. Standard perioperative management and intraoperative supervision by experienced faculty will ensure patient safety.

This study is designed as a pilot exploratory analysis that integrates human performance data, haptic sensor output, and clinical outcomes. Findings will offer the first objective evidence on how haptic feedback influences both novice and expert robotic surgeons in terms of force modulation, precision, efficiency, and safety. The results may guide the optimization of training curricula and inform the development of future robotic platforms incorporating tactile intelligence.

Conditions
Prostate Cancer
Being tested
Force-feedback on, Forece-feedback off
Medical subject headings
Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Force-feedback onDevice

    In this study, the "Force-Feedback ON" intervention refers to performing robotic-assisted radical prostatectomy using the da Vinci 5 (dV5) system with its haptic feedback function activated. When this mode is ON, miniature force sensors built into the robotic instruments continuously detect the mechanical resistance encountered at the instrument tips and transmit it back to the surgeon's hand controllers in real time.

    This tactile feedback allows the operator to feel the intensity and direction of traction or pressure applied to tissues, enabling finer motion control, reduced tissue stress, and safer dissection. In contrast, when Force Feedback is OFF, the surgeon relies solely on visual cues, as in all previous-generation robotic systems.

    Thus, "Force-Feedback ON" represents an active tactile-sensing mode designed to enhance precision, promote gentler handling, and improve training efficiency during robotic surgery.

  • Forece-feedback offDevice

    Off force-feedback function

Study groups in NCT07247175
Study groupRoleWhat they receive
Force-feedback onExperimentalNot described
Receives: Device: Force-feedback on
Force-feedback offSham comparatorNot described
Receives: Device: Forece-feedback off

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean Traction Force (Newton, N)

    Measured: intraoperatively

  2. Total Instrument Path Length (meters, m)

    Measured: intraoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Nov 2025
  2. Study start1 Jan 2026
  3. Primary completion30 Jun 2026 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07247175
Sponsor's protocol ID
2025-05-021-003
Status last verified
Feb 2026
First submitted
19 Nov 2025
Last updated
25 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Force-feedback on and Forece-feedback off in people with Prostate Cancer, run by Seong Soo Jeon at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jiwoong Yu Clinical professor (821068887981, jiwoong082.yu@samsung.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean Traction Force (Newton, N) (time frame: intraoperatively). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in